Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.

Details

Ressource 1Download: 28738904_BIB_F28D2598286B.pdf (911.25 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_F28D2598286B
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.
Journal
Journal of neuroinflammation
Author(s)
Lalive P.H., Kreutzfeldt M., Devergne O., Metz I., Bruck W., Merkler D., Pot C.
ISSN
1742-2094 (Electronic)
ISSN-L
1742-2094
Publication state
Published
Issued date
24/07/2017
Peer-reviewed
Oui
Volume
14
Number
1
Pages
144
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Multiple sclerosis (MS) is an autoimmune disorder characterized by chronic inflammation, demyelination, and neuronal damage. During autoimmunity, cytokines are important mediators of the inflammation. In this line, interleukin-27 (IL-27) modulates inflammation and can be produced directly at inflammatory sites such as in the joints during rheumatoid arthritis or in the central nervous system (CNS) during MS. While in animal models of MS, treatment with IL-27 decreases the disease severity, its role in humans is not clearly established and it is not known if IL-27 could be detected in the cerebrospinal fluid (CSF) of MS patients.
In this study, we measured IL-27 levels using a quantitative enzyme-linked immunosorbent assay in CSF of patients with relapsing remitting multiple sclerosis (RRMS), isolated optic neuritis (ON) and non-inflammatory neurological disease (NIND) as well as in the sera of healthy donors (HD) and RRMS patients undergoing different disease modifying treatments. We further confirmed by immunohistology of patient biopsies the identity of IL-27 producing cells in the brain of active MS lesions.
We observed that IL-27 levels are increased in the CSF but not in the sera of RRMS compared to HD. We confirmed that IL-27 is expressed in active MS plaques by astrocytes of MS patients.
Our results point toward a local secretion of IL-27 in the CNS that is increased during autoimmune processes. We propose that local production of IL-27 could sign the induction of a regulatory response that promotes inflammation's resolution. The effect of new immunomodulatory therapies on cerebral IL-27 production could be used to understand the biology of IL-27 in MS disease.

Keywords
Adult, Astrocytes/metabolism, Astrocytes/pathology, Central Nervous System/metabolism, Central Nervous System/pathology, Female, Glial Fibrillary Acidic Protein/metabolism, Humans, Interleukin-27/blood, Interleukin-27/cerebrospinal fluid, Interleukin-27/metabolism, Interleukins/metabolism, Male, Middle Aged, Minor Histocompatibility Antigens/metabolism, Multiple Sclerosis/pathology, Oligoclonal Bands/metabolism, Severity of Illness Index, Statistics, Nonparametric, Young Adult, Cerebrospinal fluid, Cytokines, Immunohistochemistry, Interleukin-27, Multiple sclerosis
Pubmed
Web of science
Open Access
Yes
Create date
28/08/2017 10:01
Last modification date
20/08/2019 16:19
Usage data